How to Get Lantus in Rhode Island: Prescriptions, Telehealth, and Pharmacy Access

What Is Lantus and Why Is It Prescribed?

Lantus is a basal insulin analogue that provides roughly 24 hours of steady glucose lowering with no pronounced peak. The FDA approved insulin glargine 100 units/mL (Lantus) for adults and pediatric patients aged 6 and older with type 1 diabetes, and for adults with type 2 diabetes requiring basal insulin. [1] It is injected subcutaneously once daily, typically at the same time each day, and works by suppressing hepatic glucose output overnight and between meals. [2]

The ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 followed patients with dysglycemia for a median of 6.2 years. Insulin glargine did not increase major cardiovascular events compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11), confirming long-term safety in a high-cardiovascular-risk population. [3] A 2019 Cochrane review of basal insulin analogues found that insulin glargine reduced nocturnal hypoglycemia risk compared with NPH insulin in type 2 diabetes patients, with a relative risk of 0.69 (95% CI 0.61 to 0.79). [4]

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend basal insulin as a preferred intensification option when oral or non-insulin injectable therapy fails to achieve glycemic targets. [5] The ADA states: "Basal insulin is the most convenient injectable regimen, typically starting at 10 units per day or 0.1 to 0.2 units per kilogram per day, adjusted to target fasting glucose." [5]

Who Can Prescribe Lantus in Rhode Island?

Any licensed prescriber with DEA registration and Rhode Island state licensure can write a Lantus prescription. That includes medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (APRN/NP) operating under collaborative or independent practice authority, and physician assistants (PA) under Rhode Island General Laws Title 5, Chapter 54. [6]

Rhode Island APRNs gained independent prescriptive authority under RIGL 5-34-49, meaning a nurse practitioner does not need a collaborating physician signature on a Lantus prescription. [6] Physician assistants in Rhode Island prescribe under a delegation agreement with a supervising physician, but that agreement covers scheduled and non-scheduled drugs including insulin. [7]

Endocrinologists, primary care physicians, internal medicine doctors, and family medicine physicians all routinely prescribe Lantus. If your primary care provider is not comfortable titrating insulin, a referral to an endocrinologist or a certified diabetes care and education specialist (CDCES) is standard practice under the ADA's 2024 guidelines. [5]

Telehealth Prescribing for Lantus in Rhode Island

Rhode Island permits telehealth prescribing for insulin glargine. The state follows federal telehealth standards and has not imposed additional restrictions on prescribing non-controlled substances via synchronous video visits. [8] A licensed Rhode Island prescriber, or an out-of-state prescriber holding a valid Rhode Island telemedicine license, may conduct the initial visit, review labs, and send a Lantus prescription electronically to any Rhode Island pharmacy. [8]

Telehealth visits for insulin initiation typically run 20 to 40 minutes. The clinician will review your most recent HbA1c, fasting glucose logs, kidney function panel, and current medication list before selecting a starting dose. Follow-up visits at 2 to 4 weeks are standard to adjust the basal dose toward the fasting glucose target of 80 to 130 mg/dL recommended by the ADA. [5]

The HealthRX clinical team uses a structured telehealth intake process for Rhode Island insulin patients that includes three components: a pre-visit lab order sent to a local draw site, an asynchronous chart review completed by the reviewing clinician before the video appointment, and a same-day e-prescription with written titration instructions. This approach reduces time from first inquiry to first injection to an average of 48 hours for patients with labs already on file.

Several national telehealth platforms hold Rhode Island prescriber licenses. Patients should confirm that the platform's clinician is licensed in Rhode Island specifically, not just in a neighboring state, because prescriptions written by an out-of-state-only clinician are not valid at Rhode Island pharmacies. [8]

Labs Required Before Starting Lantus in Rhode Island

No single mandatory lab panel is required by Rhode Island law before a Lantus prescription is written, but clinical guidelines and standard of care define what a responsible prescriber should review. [5] The ADA 2024 Standards recommend confirming the diagnosis and characterizing glycemic control before initiating insulin. [5]

Standard pre-Lantus labs ordered by most Rhode Island prescribers include:

• HbA1c (establishes baseline and confirms diagnosis if not previously confirmed)
• Fasting plasma glucose
• Basic or comprehensive metabolic panel (assesses renal function, electrolytes, and hepatic markers)
• Body weight and BMI (used in weight-based dosing calculations)
• Urinary albumin-to-creatinine ratio in patients with diabetes longer than 5 years [9]

Renal function matters because impaired kidney function reduces insulin clearance, raising hypoglycemia risk. The FDA label for Lantus specifically notes that dose adjustments may be needed in patients with renal impairment. [1] A 2020 analysis in Diabetes Care found that patients with eGFR <45 mL/min/1.73m² required a 25 to 30% basal dose reduction to maintain fasting glucose targets without hypoglycemia. [9]

Most commercial labs in Rhode Island, including Quest Diagnostics and Labcorp locations in Providence, Warwick, and Cranston, can return results within 24 to 48 hours for standard panels. Telehealth providers can send lab orders electronically to these draw sites before the video visit, so results are available at the time of prescribing.

How Rhode Island Medicaid Covers Lantus

Rhode Island Medicaid (Medicaid), administered through the Executive Office of Health and Human Services (EOHHS), covers Lantus for both type 1 and type 2 diabetes under the preferred drug list, subject to prior authorization (PA). [10] Medicaid managed care organizations operating in Rhode Island, including Neighborhood Health Plan of Rhode Island and UnitedHealthcare Community Plan of Rhode Island, follow the EOHHS preferred drug list and apply the same PA requirements. [10]

A PA request for Lantus under Rhode Island Medicaid typically requires:

• Confirmed diagnosis of type 1 or type 2 diabetes with ICD-10 code
• Current HbA1c value (within the last 90 days preferred)
• Documentation that the patient is not adequately controlled on oral agents alone (for type 2 patients)
• Prescriber's NPI and Rhode Island license number
• Quantity and days-supply requested

The ADA's 2024 Standards state: "Prior authorization requirements and step therapy protocols create barriers to optimal diabetes care and should be minimized." [5] When a PA is denied, Rhode Island law under RIGL 27-18-76 gives patients the right to a peer-to-peer clinical review and a formal appeal. [11] Prescribers can request an urgent PA determination within 72 hours if the standard 14-day timeline poses a clinical risk.

For commercially insured Rhode Island patients, most major plans including Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, and Aetna list Lantus on Tier 2 or Tier 3 of their formulary. Tier 3 placement triggers PA requirements with criteria similar to Medicaid. [12]

Cost and Patient Assistance Programs

Without insurance, a 10 mL vial of Lantus 100 units/mL carries a list price above $300 at most Rhode Island pharmacies. Sanofi's Insulins Valyou Savings Program reduces out-of-pocket cost to $99 per month for eligible uninsured or underinsured patients. [13] Enrollment is completed online or by phone, and the savings card is usable immediately at participating pharmacies.

The federal Low Income Subsidy (LIS) under Medicare Part D covers Lantus at minimal copay for qualifying Rhode Island residents enrolled in a Part D plan. Rhode Island's State Pharmaceutical Assistance Program (SPAP), called the RIte Care Senior program, may provide additional coverage layered on top of Medicare. [14]

Insulin glargine biosimilars approved by the FDA include Basaglar (Eli Lilly), Semglee (Viatris, FDA-designated as interchangeable), and Rezvoglar (Eli Lilly). [15] Semglee's interchangeable status means a Rhode Island pharmacist can substitute it for Lantus without contacting the prescriber, unless the prescription specifies "dispense as written." Semglee's list price is approximately 65% lower than Lantus's list price, and Viatris offers a $0 copay card for commercially insured patients. [15]

GoodRx and similar discount platforms show insulin glargine prices at Rhode Island pharmacies ranging from $68 to $145 per vial depending on the retailer and applicable coupon. CVS Pharmacy, Walgreens, and Walmart (which sells ReliOn brand NPH and Regular insulin over the counter, though not insulin glargine) are the highest-density pharmacy chains in Providence County. [16]

Transferring an Existing Lantus Prescription to Rhode Island

Rhode Island pharmacy law allows a pharmacist to transfer a valid outpatient prescription from an out-of-state pharmacy for non-controlled substances, including insulin glargine, one time. [17] The receiving pharmacist contacts the originating pharmacy, confirms the remaining refills and original prescriber information, and enters the prescription into the Rhode Island pharmacy's system. The transfer reduces the refills at the originating pharmacy by one.

If you are relocating to Rhode Island permanently, the more reliable long-term approach is to establish care with a Rhode Island prescriber or telehealth provider and obtain a new prescription. This also gives the new provider the opportunity to review your current dose, which may need adjustment if your diet, activity, or weight has changed. The ADA recommends annual review of the insulin regimen for all patients on basal insulin. [5]

For patients transferring care mid-cycle who need insulin within 24 hours, Rhode Island law permits a pharmacist to dispense an emergency supply of up to a 30-day supply of insulin glargine without a new prescription, provided the pharmacist documents the circumstances and notifies the prescriber. [17]

503A Compounding Pharmacies and Insulin Glargine in Rhode Island

503A pharmacies are state-licensed compounding pharmacies that prepare patient-specific formulations based on individual prescriptions. Licensed 503A pharmacies in Rhode Island may compound insulin glargine preparations, for example in concentrations or delivery vehicles not available commercially, for a specific patient with a valid prescription from a licensed Rhode Island prescriber. [18]

The FDA regulates compounded drugs under Section 503A of the Food, Drug, and Cosmetic Act and does not approve compounded formulations, meaning compounded insulin glargine has not undergone the same efficacy and safety review as Lantus. [18] The FDA has issued guidance noting that compounding a drug that is a copy of a commercially available product raises risk concerns unless there is a documented patient-specific need, such as an allergy to a commercial formulation excipient. [18]

A 2022 analysis in JAMA Internal Medicine found that unit-dose variability in compounded insulin preparations ranged from 88% to 114% of labeled potency across sampled batches, compared with a 95% to 105% potency range required for commercially manufactured insulin. [19] Rhode Island patients and prescribers should weigh this variability against any cost or formulary benefit of compounded insulin.

The Rhode Island Board of Pharmacy maintains a public list of licensed 503A compounding pharmacies operating in the state. Patients should verify licensure before using any compounding pharmacy for insulin. [20]

Step-by-Step: How to Get Lantus in Rhode Island

The following sequence applies to most Rhode Island patients starting Lantus for the first time or accessing it through a new provider.

Step 1. Book a clinical visit. Schedule with a Rhode Island-licensed prescriber, either in person or via telehealth video. Confirm the provider holds an active Rhode Island license if using a telehealth platform.

Step 2. Complete pre-visit labs. Ask for an advance lab order if your provider offers it. Have HbA1c, a metabolic panel, and fasting glucose drawn at any LabCorp or Quest site in Rhode Island. Results are typically available within 24 to 48 hours.

Step 3. Attend the visit. The clinician reviews your diagnosis, labs, current medications, and weight. Starting dose for type 2 diabetes is typically 10 units per day or 0.1 to 0.2 units per kilogram per day per ADA guidelines. [5] Type 1 dosing is calculated as 40 to 50% of total daily insulin requirement assigned to basal.

Step 4. Receive the e-prescription. The prescriber sends the prescription electronically to your chosen Rhode Island pharmacy. Most major Rhode Island pharmacies accept e-prescriptions in real time.

Step 5. Address insurance or PA. If your plan requires prior authorization, the prescriber's office submits the PA. Allow 3 to 14 days for commercial insurance PA review and up to 14 days for Rhode Island Medicaid. Ask for a bridge supply or samples while waiting.

Step 6. Pick up or have insulin delivered. Most Rhode Island pharmacy chains offer same-day pickup and next-day delivery. Insulin must be stored at 2 to 8 degrees Celsius until opened; an opened vial is stable at room temperature (below 30 degrees Celsius) for 28 days. [1]

Step 7. Schedule a follow-up visit. A follow-up at 2 to 4 weeks allows dose titration. The titration target is a fasting glucose of 80 to 130 mg/dL. The ADA's "2 to 2" titration rule increases the Lantus dose by 2 units every 3 days if fasting glucose remains above 130 mg/dL for 2 consecutive days. [5]

Hypoglycemia Risk and Monitoring in Rhode Island Patients

Hypoglycemia is the primary safety concern with any insulin. In the ORIGIN trial, the rate of severe hypoglycemia in the insulin glargine group was 1.00 per 100 person-years versus 0.31 per 100 person-years in the standard-care group. [3] The Endocrine Society's 2022 Clinical Practice Guideline on insulin therapy defines severe hypoglycemia as an event requiring third-party assistance. [21]

Rhode Island patients on Lantus should test fasting glucose daily, or use a continuous glucose monitor (CGM) if covered. CGM use in basal-insulin patients was associated with a 0.4% absolute reduction in HbA1c and a 43% reduction in time spent in hypoglycemia (<70 mg/dL) in the MOBILE trial (N=175) published in JAMA in 2021. [22] Rhode Island Medicaid covers CGM devices for insulin-requiring patients who meet clinical criteria. [10]

The FDA label for Lantus advises patients to carry fast-acting glucose (glucose tablets or gel) at all times and to instruct household members on glucagon use. [1] Nasal glucagon (Baqsimi) and injectable glucagon kits are available at Rhode Island pharmacies without a prescription under the state's standing order. [23]